

Datasheet: MCA87SBR775

| Description:  | MOUSE ANTI HUMAN CD45:StarBright Red 775 |  |  |
|---------------|--|--|--|
| Specificity:  | CD45                                     |  |  |
| Other names:  | LCA                                      |  |  |
| Format:       | StarBright Red 775                       |  |  |
| Product Type: | Monoclonal Antibody                      |  |  |
| Clone:        | F10-89-4                                 |  |  |
| Isotype:      | lgG2a                                    |  |  |
| Quantity:     | 100 TESTS/0.5ml                          |  |  |
|               |  |  |  |

## **Product Details**

## **Applications**

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit <a href="https://www.bio-rad-antibodies.com/protocols">www.bio-rad-antibodies.com/protocols</a>.

|                | Yes | No | Not Determined | Suggested Dilution |
|----------------|-----|----|----------------|--------------------|
| Flow Cytometry | •   |    |                | Neat               |

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

| Target Species  | Human                             |                        |                    |
|-----------------|-----------------------------------|------------------------|--------------------|
| Product Form    | Purified IgG conjugate            | ed to StarBright Red 7 | 75 - liquid        |
| Max Ex/Em       | Fluorophore                       | Excitation Max (nm)    | Emission Max (nm   |
|                 | StarBright Red 775                | 653                    | 778                |
| Preparation     | Purified IgG prepared supernatant | by affinity chromatog  | raphy on Protein A |
| Buffer Solution | Phosphate buffered sa             | aline                  |                    |
| Preservative    | 0.09% Sodium Azide                | (NaN <sub>3</sub> )    |                    |
| Stabilisers     | 1% Bovine Serum Alb               | umin                   |                    |
|                 | 0.1% Pluronic F68                 |                        |                    |
|                 | 0.1% PEG 3350                     |                        |                    |
|                 | 0.05% Tween 20                    |                        |                    |

| Immunogen                  | Human T lymphocytes.  |
|----------------------------|---|
| External Database<br>Links | UniProt: P08575 Related reagents  Entrez Gene: 5788 PTPRC Related reagents  |
| Synonyms                   | CD45  |
| Fusion Partners            | Spleen cells from immunized BALB/c mice were fused with cells of the mouse NS-1 myeloma cell line.  |
| Specificity                | Mouse anti Human CD45 antibody, clone F10-89-4 recognizes the human CD45 cell surface antigen, also known as leucocyte common antigen (LCA). CD45 is a complex molecule existing in a number of isoforms.   |
|                            | Antibodies recognizing a common epitope on all of these isoforms are termed CD45 whilst those recognizing only individual isoforms are termed CD45RA or CD45RO etc.   |
|                            | Mouse anti Human CD45 antibody, clone F10-89-4 reacts with all forms of CD45 expressed by all haematopoietic cells, except erythrocytes, having a higher level of expression on lymphocytes than on granulocytes. It is routinely tested in flow cytometry on human peripheral blood leucocytes.  |
|                            | Mouse anti Human CD45 antibody, clone F10-89-4, has been validated for use on the Genesis Cell Isolation System with the CelSelect Slide <sup>TM</sup> technology.  |
| Flow Cytometry             | Use 5µl of the suggested working dilution to label 10 <sup>6</sup> cells in 100µl. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.   |
| References                 | <ol> <li>Quenby, S et al. (1999) Pre-implantation endometrial leukocytes in women with recurrent miscarriage. Human Reprod. 14(9):2386-2391.</li> <li>Hauser, P.V. et al. (2010) Stem cells derived from human amniotic fluid contribute to acute kidney injury recovery. Am J Pathol. 177: 2011-21.</li> <li>Mallam, E. et al. (2010) Characterization of in vitro expanded bone marrow-derived mesenchymal stem cells from patients with multiple sclerosis. Mult Scler. 16: 909-18.</li> <li>Marrinucci, D. et al. (2010) Cytomorphology of circulating colorectal tumor cells:a small case series. J Oncol. 2010: 861341.</li> <li>Paul, G. et al. (2012) The adult human brain harbors multipotent perivascular mesenchymal stem cells. PLoS One. 7: e35577.</li> <li>De Schauwer, C. et al. (2012) In search for cross-reactivity to immunophenotype equine mesenchymal stromal cells by multicolor flow cytometry. Cytometry A. 81 (4): 312-23.</li> <li>Kazane, S.A. et al. (2012) Site-specific DNA-antibody conjugates for specific and sensitive immuno-PCR. Proc Natl Acad Sci U S A. 109: 3731-6.</li> <li>Spaas, J.H. et al. (2013) Culture and characterisation of equine peripheral blood mesenchymal stromal cells. Vet J. 195 (1): 107-13.</li> </ol> |

- 9. Sadarangani, A. *et al.* (2015) GLI2 inhibition abrogates human leukemia stem cell dormancy. J Transl Med. 13: 98.
- 10. Gunawardene, P. *et al.* (2015) Association Between Circulating Osteogenic Progenitor Cells and Disability and Frailty in Older Persons: The Nepean Osteoporosis and Frailty Study. <u>J Gerontol A Biol Sci Med Sci. pii: glv190.</u>
- 11. Mohamed Suhaimi, N.A. *et al.* (2015) Non-invasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients. <u>Mol Oncol. 9 (4):</u> 850-60.
- 12. Ruiz, C. *et al.* (2015) Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients. Phys Biol. 12 (1): 016008.
- 13. Gogoi P *et al.* (2016) Development of an Automated and Sensitive Microfluidic Device for Capturing and Characterizing Circulating Tumor Cells (CTCs) from Clinical Blood Samples. <u>PLoS One. 11 (1): e0147400.</u>
- 14. Gomiero, C. *et al.* (2016) Tenogenic induction of equine mesenchymal stem cells by means of growth factors and low-level laser technology. <u>Vet Res Commun. 40 (1): 39-48.</u>
- 15. Bianchessi, M. *et al.* (2016) Effect of Fibroblast Growth Factor 2 on Equine Synovial Fluid Chondroprogenitor Expansion and Chondrogenesis. Stem Cells Int. 2016: 9364974.
- 16. Branly, T. *et al.* (2017) Characterization and use of Equine Bone Marrow Mesenchymal Stem Cells in Equine Cartilage Engineering. Study of their Hyaline Cartilage Forming Potential when Cultured under Hypoxia within a Biomaterial in the Presence of BMP-2 and TGF-β1. <u>Stem Cell Rev Rep. 13 (5): 611-30.</u>
- 17. GarikipatiV, N.S. *et al.* (2018) Isolation and characterization of mesenchymal stem cells from human fetus heart. PLoS One. 13 (2): e0192244.
- 18. Shishido, S.N. *et al.* (2019) Circulating tumor cells as a response monitor in stage IV non-small cell lung cancer. <u>J Transl Med. 17 (1): 294.</u>
- 19. Welter, L. *et al.* (2020) Treatment response and tumor evolution: lessons from an extended series of multianalyte liquid biopsies in a metastatic breast cancer patient. <u>Cold Spring Harb Mol Case Stud. 6 (6): a005819.</u>
- 20. Ndacayisaba, L.J. *et al.* (2022) Enrichment-Free Single-Cell Detection and Morphogenomic Profiling of Myeloma Patient Samples to Delineate Circulating Rare Plasma Cell Clones Curr Oncol. 29 (5): 2954-72.
- 21. Shishido, S.N. *et al.* (2022) Liquid Biopsy Landscape in Patients with Primary Upper Tract Urothelial Carcinoma. <u>Cancers (Basel)</u>. 14 (12): 3007.
- 22. Chai, S. *et al.* (2022) Identification of epithelial and mesenchymal circulating tumor cells in clonal lineage of an aggressive prostate cancer case. <u>NPJ Precis Oncol. 6 (1): 41.</u>
- 23. Zhu, J. *et al.* (2022) Sequential Method for Analysis of CTCs and Exosomes from the Same Sample of Patient Blood. <u>ACS Omega. 7 (42): 37581-88.</u>
- 24. Setayesh, S.M. *et al.* (2022) Multianalyte liquid biopsy to aid the diagnostic workup of breast cancer. NPJ Breast Cancer. 8 (1): 112.
- 25. Ndacayisaba, L.J. *et al.* (2022) Characterization of BCMA Expression in Circulating Rare Single Cells of Patients with Plasma Cell Neoplasms. <u>Int J Mol Sci. 23 (21): 13427.</u>
- 26. Qi, E. *et al.* (2023) Investigation of liquid biopsy analytes in peripheral blood of individuals after SARS-CoV-2 infection. <u>EBioMedicine</u>. 90: 104519.
- 27. Seo, J. *et al.* (2023) Plasticity of circulating tumor cells in small cell lung cancer. <u>Sci Rep. 13 (1): 11775.</u>
- 28. Setayesh, S.M. *et al.* (2023) Targeted single-cell proteomic analysis identifies new liquid biopsy biomarkers associated with multiple myeloma. <u>NPJ Precis Oncol. 7 (1): 95.</u>

29. Welter, L. *et al.* (2023) Cell State and Cell Type: Deconvoluting Circulating Tumor Cell Populations in Liquid Biopsies by Multi-Omics. Cancers (Basel). 15 (15): 3949.

- 30. Shishido, S.N. *et al.* (2024) Cancer-related cells and oncosomes in the liquid biopsy of pancreatic cancer patients undergoing surgery. <u>NPJ Precis Oncol. 8 (1): 36.</u>
- 31. Bai, L. *et al.* (2024) Longitudinal tracking of circulating rare events in the liquid biopsy of stage III-IV non-small cell lung cancer patients. Discov Oncol. 15 (1): 142.
- 32. Shishido, S.N. *et al.* (2024) Determining the efficacy of ExThera Seraph100 blood filtration in patients diagnosed with pancreatic cancer through the liquid biopsy <u>BJC</u> Reports. 2: 47.
- 33. Moellerberndt, J. *et al.* (2024) Impact of platelet lysate on immunoregulatory characteristics of equine mesenchymal stromal cells. Front Vet Sci. 11: 1385395.
- 34. Schmidt, M.J. *et al.* (2024) Polyploid cancer cells reveal signatures of chemotherapy resistance. bioRxiv. Aug 23 [Preprint].

| Storage           | Store at +4°C. DO NOT FREEZE.   |
|-------------------|---|
|                   | This product should be stored undiluted.  |
| Guarantee         | 12 months from date of despatch   |
| Acknowledgements  | This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts |
| Health And Safety | Material Safety Datasheet documentation #20471 available at:                                    |
| Information       | https://www.bio-rad-antibodies.com/SDS/MCA87SBR775  |
|                   | 20471   |
| Regulatory        | For research purposes only  |

# **Related Products**

### **Recommended Useful Reagents**

HUMAN SEROBLOCK (BUF070A) HUMAN SEROBLOCK (BUF070B)

North & South Tel: +1 800 265 7376

America Fax: +1 919 878 3751

Worldwide

Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Europe

Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50

Email: antibody\_sales\_us@bio-rad.com

Email: antibody\_sales\_uk@bio-rad.com

Email: antibody\_sales\_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets 'M426075:231120'

#### Printed on 29 Nov 2024

© 2024 Bio-Rad Laboratories Inc | Legal | Imprint